TACE performed in patients with a single nodule of Hepatocellular Carcinoma

Terzi, Eleonora; Piscaglia, Fabio; Forlani, Ludovica; Mosconi, Cristina; Renzulli, Matteo; Bolondi, Luigi; Golfieri, Rita

doi:10.1186/1471-2407-14-601

BMC Cancer

Table 5 Univariate survival analysis

From: TACE performed in patients with a single nodule of Hepatocellular Carcinoma

Variable	Survival (%)			Median survival (95% C.I.)	P
Variable	1-yr	3-yr	5-yr	Median survival (95% C.I.)	P
Gender
Male	84	45	29	26.0 (16.7 – 35.3)	0.975
Female	88	63	20	41.0 (34.9 – 47.1)	0.975
Age, yr
<64	80	35	26	24.0 (21.5 – 26.5)	0.453
≥64	88	59	26	40.0 (36.2 – 43.8)	0.453
Cause of disease
Alcohol	81	28	21	24.0 (22.5 – 25.5)	0.081
Non alcohol	86	56	27	40.0 (33.0 – 47.0)	0.081
TACE selectivity
Lobar	87	58	58	44.0 (0 –104.8)	0.823
Selective	87	51	29	36.0 (25.8 – 46.2)
Superselective	82	49	27	26.0 (10.2 – 41.8)
Milan criteria
Within (≤5.0 cm)	90	54	28	37.0 (30.2 – 43.8)	0.003
Beyond (>5.0 cm)	46	18	10	6.0 (0 – 17.3)	0.003
Portal vein thrombosis
Absent	86	50	24	36.0 (24.0 – 48.0)	0.876
Bland thrombosis	78	52	39	36.0 (4.6 – 67.4)	0.876
AFP, ng/mL
<14.5	89	58	39	41.0 (23.0 – 59.0)	0.052
≥14.5	79	43	22	25.0 (19.5 – 30.5)	0.052
Ascites
Absent	92	55	28	37.0 (29.0 – 45.0)	0.013
Present	57	32	16	15.0 (3.0 – 27.0)	0.013
Serum total bilirubin, mg/dL
<1.34	92	62	31	41.0 (36.6 – 45.4)	0.026
≥1.34	74	32	18	23.0 (18.1 – 27.9)	0.026
Serum albumin, g/dL
<3.60	81	40	20	24.0 (18.3 – 29.6)	0.340
≥3.60	87	55	29	40.0 (32.4 – 47.6)	0.340
Serum INR
<1.28	89	58	27	40.0 (34.5 – 45.5)	0.211
≥1.28	80	40	23	25.0 (18.8 – 31.2)	0.211
Hepatic function
CPT-A	93	60	26	40.0 (36.1 – 43.9)	0.075
CPT-B	83	47	22	21.0 (15.3 – 26.7)	0.075
Hepatic function. Pts Milan in patients
CPT-A	97	60	31	41.0 (37.2 – 44.8)	0.053
CPT-B	74	35	22	21.0 (14.3 – 27.7)	0.053
Performance status
0	92	61	34	36.0 (24.7 – 47.3)	0.080
1	78	41	18	28.0 (11.2 – 44.7)	0.080
PS. Patients Milan In
0	91	55	31	41.0 (31.5 – 50.5)	0.029
1	83	50	0	28.0 (11.2 – 44.8)	0.029
BCLC stage
0 – A	91	55	31	41.0 (31.5 – 50.5)	0.002
B	46	18	10	6.0 (0 – 17.3)
C	83	47	0	28.0 (11.2 – 44.8)
MELD score
< 11	92	61	34	41.0 (27.0 – 55.0)	0.060
≥ 11	78	41	18	25.0 (21.5 – 28.5)	0.060
Child-Pugh increase post-TACE
Absent	92	60	35	41.0 (33.6 – 48.3)	0.003
≥ 1 point	83	35	14	22.0 (10.3 – 33.6)	0.003
MELD increase post-TACE
Absent	94	39	44	44.0 (24.5 – 63.4)	0.003
≥ 1 point	80	43	17	25.0 (17.9 – 32.0)	0.003
Tumor response
CR	92	54	30	37.0 (25.4 – 48.6)	0.048
Non–CR	72	45	17	28.0 (17.8 – 38.2)	0.048
Recurrence
Absent	88	57	57	36.0 (12.1 – 59.9)	0.817
Present	94	72	55	40.0 (26.9 – 53.1)	0.817
Recurrence type
Local	95	63	32	42.0 (31.4 – 52.6)	0.312
Distant intrahepatic	100	53	39	44.0 (9.5 – 78.5)
Local + distant intrahepatic	82	45	11	31.0 (12.1 – 49.9)

Patients submitted to liver transplant (LT) were excluded from the analysis (34 patients). The assessment of tumor response was considered at 1 month after TACE. In the analysis of survival according to tumor response also patients not evaluable were excluded from the analysis.
Abbreviations: HCV hepatitis C virus, TACE transarterial chemoembolization, AFP Alpha-fetoprotein, INR international normalized ratio, CPT Child-Pugh-Turcotte score, BCLC Barcelona Clinic Liver Cancer, MELD Model for end stage liver disease, CR complete response, PR partial response, PD progressive disease, PS = Performance Statsus, BCLC Barcelona Clinic Liver Cancer.
P<0.05 are reported as bold numbers.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com